Literature DB >> 16416221

TP53 gene mutations are rare in nondysplastic Barrett's esophagus.

Kamila Novotna1, Marie Trkova, Alexandr Pazdro, Milan Smejkal, Alzbeta Soukupova, Daniela Kodetova, Premysl Smejkal, Zdenek Sedlacek.   

Abstract

In search of potential prognostic markers, we analyzed a large series of tissues of Barrett's esophagus and samples of adenocarcinomas arising in the terrain of Barrett's esophagus for TP53 gene mutations by direct sequencing of exons 5 to 9 of the TP53 gene. While 9 of 21 adenocarcinomas tested (42.9%) contained a TP53 mutation, none of 24 samples from Barrett's esophagus were mutated. This observation suggests that TP53 gene mutation may be a relatively late event in the progression from nondysplastic Barrett's esophagus to adenocarcinoma of esophagus. Therefore, TP53 gene mutations alone are not likely to represent a widely useful prognostic marker of the risk of progression to malignancy, at least not in Barrett's esophagus without dysplasia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16416221     DOI: 10.1007/s10620-006-3093-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.

Authors:  Y S Bian; M C Osterheld; F T Bosman; J Benhattar; C Fontolliet
Journal:  Mod Pathol       Date:  2001-05       Impact factor: 7.842

Review 2.  Role of p53 assessment in management of Barrett's esophagus.

Authors:  A K Kubba; N A Poole; A Watson
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

3.  Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.

Authors:  M V González; M L Artímez; L Rodrigo; C López-Larrea; M J Menéndez; V Alvarez; R Pérez; M F Fresno; M J Pérez; A Sampedro; E Coto
Journal:  J Clin Pathol       Date:  1997-03       Impact factor: 3.411

4.  Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples.

Authors:  F P Wikman; M L Lu; T Thykjaer; S H Olesen; L D Andersen; C Cordon-Cardo; T F Orntoft
Journal:  Clin Chem       Date:  2000-10       Impact factor: 8.327

Review 5.  The UMD-p53 database: new mutations and analysis tools.

Authors:  Christophe Béroud; Thierry Soussi
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

6.  p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia.

Authors:  K Neshat; C A Sanchez; P C Galipeau; P L Blount; D S Levine; G Joslyn; B J Reid
Journal:  Gastroenterology       Date:  1994-06       Impact factor: 22.682

7.  Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology.

Authors:  G J S Jenkins; S H Doak; A P Griffiths; N Tofazzal; V Shah; J N Baxter; J M Parry
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

8.  Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study.

Authors:  Alan G Casson; Susan C Evans; Amy Gillis; Geoffrey A Porter; Paul Veugelers; S Jane Darnton; Duane L Guernsey; Pierre Hainaut
Journal:  J Thorac Cardiovasc Surg       Date:  2003-05       Impact factor: 5.209

9.  Evolution of neoplastic cell lineages in Barrett oesophagus.

Authors:  M T Barrett; C A Sanchez; L J Prevo; D J Wong; P C Galipeau; T G Paulson; P S Rabinovitch; B J Reid
Journal:  Nat Genet       Date:  1999-05       Impact factor: 38.330

Review 10.  Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma.

Authors:  G J S Jenkins; S H Doak; J M Parry; F R D'Souza; A P Griffiths; J N Baxter
Journal:  Br J Surg       Date:  2002-07       Impact factor: 6.939

View more
  5 in total

1.  Risk factors associated with Barrett's epithelial dysplasia.

Authors:  Mikiko Fujita; Yuri Nakamura; Saeko Kasashima; Maiko Furukawa; Ryoichi Misaka; Hikaru Nagahara
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Targeted genetic and epigenetic profiling of esophageal adenocarcinomas and non-dysplastic Barrett's esophagus.

Authors:  Rita Pinto; Tobias Hauge; Marine Jeanmougin; Heidi D Pharo; Stine H Kresse; Hilde Honne; Sara B Winge; May-Britt Five; Theresa Kumar; Tom Mala; Truls Hauge; Egil Johnson; Guro E Lind
Journal:  Clin Epigenetics       Date:  2022-06-14       Impact factor: 7.259

3.  Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.

Authors:  Matthew D Stachler; Nicholas D Camarda; Christopher Deitrick; Anthony Kim; Agoston T Agoston; Robert D Odze; Jason L Hornick; Anwesha Nag; Aaron R Thorner; Matthew Ducar; Amy Noffsinger; Richard H Lash; Mark Redston; Scott L Carter; Jon M Davison; Adam J Bass
Journal:  Gastroenterology       Date:  2018-03-31       Impact factor: 22.682

4.  Individual patient oesophageal cancer 3D models for tailored treatment.

Authors:  John H Saunders; David Onion; Pamela Collier; Matthew S Dorrington; Richard H Argent; Philip A Clarke; Alex M Reece-Smith; Simon L Parsons; Anna M Grabowska
Journal:  Oncotarget       Date:  2017-04-11

5.  Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Eric Smith; Neville J De Young; Sandra J Pavey; Nicholas K Hayward; Derek J Nancarrow; David C Whiteman; B Mark Smithers; Andrew R Ruszkiewicz; Andrew D Clouston; David C Gotley; Peter G Devitt; Glyn G Jamieson; Paul A Drew
Journal:  Mol Cancer       Date:  2008-10-02       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.